Established entire internal recruiting structure for manufacturer of the Impella, a breakthrough percutaneously inserted ventricular assist device (VAD) that enables safer, more minimally invasive procedures for patients with severe heart failure, cardiogenic shock and high-risk percutaneous coronary intervention (PCI). Abiomed (ABMD) is a pioneer and global leader in healthcare technology and innovation, with a mission of RECOVERING HEARTS AND SAVING LIVES. The company is focused on developing ground-breaking technologies designed to assist or replace the life-sustaining pumping function of the failing heart. Accomplishments Include: Directed 108% increase in total U.S. headcount during tenure. Abiomed now employs more than 1,300 worldwide. Abiomed named 8th Fastest-growing company in the World and the No. 1 fastest-growing medical device company in the World by Fortune in 2016. www.abiomed.com

Lead recruitment efforts in the search for motivated, high-quality sales, sales management, clinical specialist and engineering candidates who have a passion for and experience in interventional cardiology and the cath lab. Abiomed is a pioneer and global leader in healthcare technology and innovation, with a mission of RECOVERING HEARTS AND SAVING LIVES. The company is focused on developing ground-breaking technologies designed to assist or replace the life-sustaining pumping function of the failing heart. Abiomed's portfolio of products and services offer healthcare professionals an array of choices across a broad clinical spectrum. From the world’s first total replacement heart to the World’s Smallest Heart Pump, 1/100th the size of the heart with rapid and simple insertion, Abiomed is dedicated to finding ways to bring the most advanced and beneficial technology to patients and physicians.

Corbus(NASDAQ:CRBP) is a Phase 3 clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat life threatening ("orphan") inflammatory-fibrotic diseases with clear unmet needs. Our lead product Anabasum, is an endocannabinoid mimetic (CB2 agoinist) that is designed to resolve inflammation and halt fibrosis. The drug recently completed Phase 2 with positive results in cystic fibrosis and systemic sclerosis. We expect to commence a Phase 3 study in systemic sclerosis and a Phase 2B in cystic fibrosis in the fourth quarter of 2017. Phase 2 clinical results in dermatomyositis are expected in the third quarter of 2017 and a Phase 2 trial in systemic lupus erythematosus is expected to comment in the 2nd half of 2017. www.corbuspharma.com

* Conducted candidate recruitment and client development efforts for the placement of medical sales, sales management, clinical specialist, marketing, operations and engineering professionals for a leading, well-respected recruiting agency servicing top companies ranging from startups to Fortune 100. * Sourced, recruited, interviewed and placed above-mentioned professionals nationwide. * Developed, nurtured, secured and maintained long-term client relationships to gain job requisitions. * Negotiated client contracts. Negotiated salary & benefit packages between clients and candidates. * Reported to and informed executive management team on all recruitment activities and results.